A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Anetumab ravtansine (Primary) ; Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 03 Jul 2019 Planned End Date changed from 30 Apr 2019 to 30 Jun 2020.
- 03 Jul 2019 Planned primary completion date changed from 30 Apr 2019 to 30 Jun 2020.
- 19 Jul 2018 New trial record